文献速递关节外科

2021 Chitranjan S. Ranawat奖:骨内注射万古霉素在90天随访中降低初次全膝关节置换术后假体周围关节感染

2021 Chitranjan S. Ranawat Award: Intraosseous vancomycin reduces periprosthetic joint infection in primary total knee arthroplasty at 90-day follow-up.
PubMed 文献 · Bone Joint J · 2021-01-01

该回顾性研究纳入1060例初次全膝关节置换术患者,比较静脉注射与骨内注射万古霉素的假体周围关节感染(PJI)发生率。至少90天随访时,静脉组PJI发生率为1.4%(8膝),骨内组为0.22%(1膝),差异有统计学意义(p=0.047)。骨内注射万古霉素联合第一代头孢菌素是安全有效的替代方案。

要点

  • 骨内注射万古霉素组90天PJI发生率0.22%,显著低于静脉组的1.4%(p=0.047)。
  • 骨内注射方法为止血带充气后、切皮前将500mg万古霉素溶于150ml生理盐水注入胫骨近端。
  • 两组在年龄、性别、BMI及基线合并症方面无差异,骨内注射安全可行。

核心结论

  • 骨内注射万古霉素联合第一代头孢菌素可降低初次全膝关节置换术后90天PJI发生率,且安全有效。

研究设计与样本

  • 回顾性研究,纳入2016年5月至2020年7月间1060例初次全膝关节置换术患者,静脉组572例,骨内组488例,最少随访30天。

主要发现

  • 至少90天随访时,静脉组PJI发生率为1.4%(8膝),骨内组为0.22%(1膝),p=0.047。
  • 两组年龄、性别、BMI及基线合并症无差异。

关键数值与推荐

  • 静脉组:切皮前1小时内给予15 mg/kg万古霉素静脉滴注。
  • 骨内组:止血带充气后、切皮前将500 mg万古霉素溶于150 ml生理盐水注入胫骨近端。
  • 所有患者均额外接受一剂第一代头孢菌素。

临床怎么用

  • 骨内注射万古霉素可在止血带充气后、切皮前给予,避免静脉给药时机和剂量的 logistics 挑战。

局限性

  • 回顾性、多外科医生研究,存在局限性,早期结果令人鼓舞但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Infection complicating primary total knee arthroplasty (TKA) is a common reason for revision surgery, hospital readmission, patient morbidity, and mortality. Increasing incidence of methicillin-resistant Staphylococcus aureus (MRSA) is a particular concern. The use of vancomycin as prophylactic agent alone or in combination with cephalosporin has not demonstrated lower periprosthetic joint infection (PJI) rates, partly due to timing and dosing of intravenous (IV) vancomycin administration, which have proven important factors in effectiveness. This is a retrospective review of a consecutive series of primary TKAs examining incidence of PJI, adverse reactions, and complications using IV versus intraosseous (IO) vancomycin at 30-day, 90-day, and one-year follow-up. METHODS: A retrospective review of 1,060 patients who underwent TKA between May 2016 to July 2020 was performed. There were 572 patients in the IV group and 488 in the IO group, with minimal 30 days of follow-up. Patients were followed up at regularly scheduled intervals (two, six, and 12 weeks). No differences between groups for age, sex, BMI, or baseline comorbidities existed. The IV group received an IV dose of 15 mg/kg vancomycin given over an hour preceding skin incision. The IO group received a 500 mg dose of vancomycin mixed in 150 ml of normal saline, injected into proximal tibia after tourniquet inflation, before skin incision. All patients received an additional dose of first generation cephalosporin. Evaluation included preoperative and postoperative serum creatinine values, tourniquet time, and adverse reactions attributable to vancomycin. RESULTS: Incidence of PJI with minimum 90-day follow-up was 1.4% (eight knees) in the IV group and 0.22% (one knee) in IO group (p = 0.047). This preliminary report demonstrated an reduction in the incidence of infection in TKA using IO vancomycin combined with a first-generation cephalosporin. While the study suffers from limitations of a retrospective, multi-surgeon investigation, early findings are encouraging. CONCLUSION: IO delivery of vancomycin after tourniquet inflation is a safe and effective alternative to IV administration, eliminating the logistical challenges of timely dosing. Cite this article: Bone Joint J 2021;103-B(6 Supple A):13-17.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Park KJ, Chapleau J, Sullivan TC, et al. 2021 Chitranjan S. Ranawat Award: Intraosseous vancomycin reduces periprosthetic joint infection in primary total knee arthroplasty at 90-day follow-up. Bone Joint J. 2021. PMID: 34053300. doi:10.1302/0301-620X.103B6.BJJ-2020-2401.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。